+1 Recommend
    • Review: found
    Is Open Access

    Review of 'Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment'

    Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deploymentCrossref
    The article can be easily finished by one sitting. It provides the policies so understandably.
    Average rating:
        Rated 4.5 of 5.
    Level of importance:
        Rated 5 of 5.
    Level of validity:
        Rated 5 of 5.
    Level of completeness:
        Rated 4 of 5.
    Level of comprehensibility:
        Rated 4 of 5.
    Competing interests:

    Reviewed article

    • Record: found
    • Abstract: found
    • Article: not found

    Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment

    The COVID-19 pandemic is unlikely to end until there is global roll-out of vaccines that protect against severe disease and preferably drive herd immunity. Regulators in numerous countries have authorised or approved COVID-19 vaccines for human use, with more expected to be licensed in 2021. Yet having licensed vaccines is not enough to achieve global control of COVID-19: they also need to be produced at scale, priced affordably, allocated globally so that they are available where needed, and widely deployed in local communities. In this Health Policy paper, we review potential challenges to success in each of these dimensions and discuss policy implications. To guide our review, we developed a dashboard to highlight key characteristics of 26 leading vaccine candidates, including efficacy levels, dosing regimens, storage requirements, prices, production capacities in 2021, and stocks reserved for low-income and middle-income countries. We use a traffic-light system to signal the potential contributions of each candidate to achieving global vaccine immunity, highlighting important trade-offs that policy makers need to consider when developing and implementing vaccination programmes. Although specific datapoints are subject to change as the pandemic response progresses, the dashboard will continue to provide a useful lens through which to analyse the key issues affecting the use of COVID-19 vaccines. We also present original data from a 32-country survey (n=26 758) on potential acceptance of COVID-19 vaccines, conducted from October to December, 2020. Vaccine acceptance was highest in Vietnam (98%), India (91%), China (91%), Denmark (87%), and South Korea (87%), and lowest in Serbia (38%), Croatia (41%), France (44%), Lebanon (44%), and Paraguay (51%).

      Review information

      This work has been published open access under Creative Commons Attribution License CC BY 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Conditions, terms of use and publishing policy can be found at www.scienceopen.com.

      Review text

      The first impression that draws the paper is its smooth progress of language and thought.

      The paper is a health policy communique. The authors have tried with their utmost effort to make graphical presentations of the data.

      This is more like a conceptual paper than a pure research based. The inference of various convenient literatures has strengthened the defenses of the paper.

      The paper has dug out the possible and feasible ways to make the vaccine reach. If this policy is not adopted, there must prevail perils, according to the presentations of data, though the perils are not highlighted so masterfully.   

      The overall presentation of the data is trusted and there is no clear trace of ambiguity of graphical presentations.


      Comment on this review

      Version and Review History